News | Catheters | April 21, 2022

MIVI Neuroscience Launches Largest Study Yet of its Aspiration Catheter for Thrombus Removal

The AQUAS Registry is a prospective registry of 250 subjects conducted across up to 12 high-volume, comprehensive stroke centers in Europe.

MIVI Neuroscience, Inc., innovator of the next generation of neurointerventional medical devices, today announced the first patient enrollments in a multicenter clinical study to assess the safety and performance of the Q Aspiration Catheter used in a combined aspiration with stent-retriever technique for thrombus removal in patients who have suffered an acute ischemic stroke.  

Q Aspiration Catheter


April 21, 2022 – MIVI Neuroscience, Inc., innovator of the next generation of neurointerventional medical devices, today announced the first patient enrollments in a multicenter clinical study to assess the safety and performance of the Q Aspiration Catheter used in a combined aspiration with stent-retriever technique for thrombus removal in patients who have suffered an acute ischemic stroke.   

The AQUAS Registry is a prospective registry of 250 subjects conducted across up to 12 high-volume, comprehensive stroke centers in Europe. It is the largest study of a MIVI device to date.  The study is expected to conclude within 12 months.

In the United States, approximately 50% of ischemic stroke interventions employ a combined technique; the other 50% use only an aspiration catheter. “In both cases, we want the physician to reach for the Q Aspiration Catheter because it offers the highest aspiration power available and a simpler setup,” said Bob Colloton, CEO of MIVI Neuroscience. “This registry is a massive undertaking, involving a large group of stroke experts, patients, and two important partners: study organizer Angionautix and Acandis, manufacturer of the stent retriever that will be used with our catheter. We believe that the Q Aspiration Catheter is the physician’s best choice, and the AQUAS Registry will provide us with additional data on its safety and performance.”

Led by Dr. Sebastian Remollo Friedemann of Hospital Universitari Germans Trias I Pujol in Barcelona, the registry will assess the safety and performance of the Q Aspiration Catheter combined with the Acandis Aperio stent-retriever in treating ischemic stroke patients.  

“The Q Aspiration Catheter is a powerful solution for stroke treatment,” said Dr. Remollo.  “I’m looking forward to solid evidence from the study that adds to my personal experience with the product and advancing the approach to thrombus removal.”

The Q Aspiration Catheter is CE-marked in Europe and under Investigational Device Exemption in the United States. 

For more information: www.mivineuro.com


Related Content

News | Cardiovascular Clinical Studies

May 23, 2024 — A newly-published peer-reviewed study in the Journal of the American Heart Association, JAHA, found that ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — Global Heart Hub, the international alliance of heart patient organizations, announced the first findings ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 21, 2024 — A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging ...

Home May 21, 2024
Home
News | Cardiovascular Clinical Studies

May 20, 2024 — Cardiologist Brendan Carry, MD, and a team of Danville, PA-based Geisinger Medical Center physicians have ...

Home May 20, 2024
Home
News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
News | Cardiovascular Clinical Studies

May 17, 2024 — Royal Philips, a global leader in health technology, is presenting new retrospective study results ...

Home May 17, 2024
Home
News | Cardiovascular Clinical Studies

May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the ...

Home May 15, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

Home May 14, 2024
Home
Subscribe Now